Repositioning Candidate Details
| Candidate ID: | R0410 |
| Source ID: | DB01115 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Nifedipine |
| Synonyms: | Nifedipine |
| Molecular Formula: | C17H18N2O6 |
| SMILES: | COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC |
| Structure: |
|
| DrugBank Description: | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to . Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is . Nifedipine was granted FDA approval on 31 December 1981. |
| CAS Number: | 21829-25-4 |
| Molecular Weight: | 346.3346 |
| DrugBank Indication: | Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension. |
| DrugBank Pharmacology: | Nifedipine is an inhibitor of L-type voltage gated calcium channels that reduces blood pressure and increases oxygen supply to the heart. Immediate release nifedipine's duration of action requires dosing 3 times daily. Nifedipine dosing is generally 10-120mg daily. Patients should be counselled regarding the risk of excessive hypotension, angina, and myocardial infarction. |
| DrugBank MoA: | Nifedipine blocks voltage gated L-type calcium channels in vascular smooth muscle and myocardial cells. This blockage prevents the entry of calcium ions into cells during depolarization, reducing peripheral arterial vascular resistance and dilating coronary arteries. These actions reduce blood pressure and increase the supply of oxygen to the heart, alleviating angina. |
| Targets: | Voltage-dependent L-type calcium channel subunit alpha-1C inhibitor; Nuclear receptor subfamily 1 group I member 2 agonist; Calmodulin inhibitor; Voltage-dependent L-type calcium channel subunit alpha-1D inhibitor; Voltage-dependent L-type calcium channel subunit alpha-1S inhibitor; Voltage-dependent L-type calcium channel subunit beta-2 inhibitor; Potassium voltage-gated channel subfamily D member 3 inhibitor; Voltage-dependent T-type calcium channel inhibitor |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |